A randomized, placebo-controlled trial of alagebrium in patients with insulin-dependent type 1 diabetes and microalbuminuria

Trial Profile

A randomized, placebo-controlled trial of alagebrium in patients with insulin-dependent type 1 diabetes and microalbuminuria

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Aug 2015

At a glance

  • Drugs Alagebrium chloride (Primary)
  • Indications Diabetic nephropathies; Proteinuria
  • Focus Biomarker; Therapeutic Use
  • Sponsors Synvista Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Feb 2009 Status changed from recruiting to discontinued, according to clinicaltrials.gov; the reason stated was financial constraint.
    • 21 Aug 2008 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top